Design, synthesis, evaluation and molecular modeling of quinazoline derivatives bearing amino acids as small-molecule PD-L1 inhibitors.[J].Journal of Computer-Aided Molecular Design,2025,39:55.

Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors.[J].Journal of Enzyme Inhibition and Medicinal Chemistry,2025,40(1):2461190.

Design, Synthesis, and Evaluation of 8-(o-Tolyl)quinazoline Derivatives as Small-Molecule PD-1/PD-L1 Antagonists.ACS Medicinal Chemistry Letters,2024,15518-523.

Design, synthesis and biological evaluation of VEGFR-2/HDAC dual inhibitors as multitargeted antitumor agents based on fruquintinib and vorinostat.RSC Adv.,2023,1328462-28480.

Advances in nonclassical phenyl bioisosteres for drug structural optimization.Future Medicinal Chemistry,2022,141681-1692.

Advances in research on 3C-like protease (3CLpro) inhibitors against SARS-CoV-2 since 2020.RSC Med. Chem.,2022,149-21.

Discovery of quinazoline derivatives as novel small-molecule inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction.European Journal of Medicinal Chemistry,2022,229113998.

Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy.Future Med. Chem.,2021,1497-113.

Design, Synthesis, Biological Activity and Molecular Docking Study of Coumarin Derivatives Bearing 2-Methyl-Biphenyl Moiety.Chem. Res. Chinese Universities,2019,35410-417.

Semicarbazone derivatives bearing phenyl moiety: synthesis, anticancer activity, cell cycle, apoptosis-inducing and metabolic stability study.Chemical & Pharmaceutical Bulletin,2019,67351-360.